Global drug approvals through the first half (H1) of 2026 reached 261, the third-highest H1 total in BioWorld’s records behind 2021’s 288 and 2025's 271, and ahead of 2022’s 256. June was the standout month of the first six months at 64 approvals, the highest single month in BioWorld’s records and a notable acceleration from May’s 43.